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Edited by Ned ManteiAbstract Retinoids are known inhibitors of epithelial cell pro-
liferation. Previous studies indicate that Kru¨ppel-like factor 5
(KLF5) is a pro-proliferative transcription factor. Here, we
examined the eﬀect of all-trans retinoid acid (ATRA) on prolif-
eration of the intestinal epithelial cell line, IEC6. Treatment of
IEC6 cells with ATRA inhibited their proliferation due to G1 cell
cycle arrest. This inhibition was correlated with a decrease in the
levels of KLF5 mRNA and promoter activity. In contrast, consti-
tutive expression of KLF5 in stably transfected IEC6 cells with a
KLF5-expressing plasmid driven by a viral promoter abrogated
the growth inhibitory eﬀect of ATRA. Moreover, ATRA inhib-
ited proliferation of several human colon cancer cell lines with
high levels of KLF5 expression but not those with low levels of
KLF5 expression. Our results indicate that KLF5 is a potential
mediator for the inhibitory eﬀect of ATRA on intestinal epithel-
ial cell proliferation.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Kru¨ppel-like factors (KLFs) belong to a class of zinc ﬁnger-
containing transcription factors that exhibit homology to the
general transcription factor Sp1 [1–4]. Numerous studies indi-
cate that KLFs play important roles in regulating cell prolifer-
ation and diﬀerentiation. Two KLFs are present at high levels
in the intestinal epithelium although in diﬀerent locations –
KLF4 is expressed primarily in the terminally diﬀerentiated,
post-mitotic epithelial cells [5,6] and KLF5 in the proliferating
crypt compartment [7,8]. The two proteins also exhibit diﬀer-
ent biological properties – KLF4 is an inhibitor of cell prolif-Abbreviations: APL, acute promyelocytic leukemia; ATRA, all-trans
retinoic acid; CMV, cytomegalovirus; DPBS, Dulbeccos phosphate
buﬀered saline; FACS, ﬂuorescence-activated cell sorting; FBS, fetal
bovine serum; GAPDH, glyceraldehyde-3-phosphate dehydrogenase;
HA, hemagglutinin A; IEC, intestinal epithelial cells; KLF5, Kru¨ppel-
like factor 5; MAPK, mitogen-activated protein kinase; PI, propidium
iodide; PKC, protein kinase C; RAR, retinoic acid receptor; RARE,
retinoic acid response element; RXR, retinoic X receptor
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doi:10.1016/j.febslet.2004.10.079eration [5,9,10] but KLF5 stimulates cell proliferation when
overexpressed [11]. Thus, the two KLFs may function to coor-
dinate proliferation of the intestinal epithelial cells (IEC).
Retinoids, and other derivatives of vitamin A, are known to
have important functions in regulating diﬀerentiation and pro-
liferation. The eﬀects of retinoids are mediated by nuclear
receptors, such as retinoic acid receptors (RARs) and retinoic
X receptors (RXRs) [12]. Because of their potent growth-sup-
pressive eﬀects, retinoids are used as a chemotherapeutic or
chemopreventive agent in the treatment of a variety of disor-
ders in preclinical and clinical settings [13,14]. All-trans reti-
noic acid (ATRA) is one type of retinoid that binds
preferentially to RARs, which form homodimers or heterodi-
mers with RXRs and interact with retinoic acid response ele-
ments (RAREs) to mediate cellular response [15–17]. ATRA
is an eﬀective chemotherapeutic drug for the treatment of
acute promyelocytic leukemia (APL) [18]. In addition, ATRA
exhibits an inhibitory eﬀect in a number of colon cancer cell
lines [19–21]. Therefore, ATRA may potentially serve as an
anti-proliferative agent in the treatment of cancerous cells.
Previous studies have shown that overexpression of KLF5
stimulates proliferation of intestinal epithelial cells, IEC-18,
and NIH 3T3 ﬁbroblasts [11,22]. Moreover, RARa interacts
with KLF5 and RAR ligands modulate KLF5 transcriptional
activity and consequent cellular proliferation [23]. In the cur-
rent study, we aimed at determining whether ATRA may mod-
ulate proliferation of intestinal epithelial cells, IEC6, and
whether such modulation may be dependent on KLF5.2. Materials and methods
2.1. Cell lines
Non-transformed rat intestinal epithelial cells, IEC6, and the human
colon cancer cell lines, DLD1, HT29 and RKO, were purchased from
the American Type Culture Collection (Manassas, VA). The colon
cancer cell line, Caco2-BBE, was previously described [24]. Stable
transfection of IEC6 cells was performed by lipofection using pBK-
CMV-KLF5-HA [7,11]. Transfected cells were selected with 1 mg/ml
G418 and pooled for experimentation. Cells were treated with media
containing 10 lM ATRA or ethanol control for the stated periods.2.2. Cell proliferation assay
Cells were maintained in Dulbeccos modiﬁed Eagles medium sup-
plemented with 5% fetal bovine serum (FBS), 0.1 U/ml insulin, and
1% streptomycin. Cells were seeded at a density of 100000 cells/6-well
dish and treated with ATRA or ethanol for the stated periods of time.
Each day, cells were collected, washed with Dulbeccos phosphate-buﬀ-




































Fig. 1. The eﬀect of ATRA on proliferation and cell cycle proﬁles of
IEC6 cells. (A) IEC6 cells were seeded at a density of 105 cells/6-well
dish and maintained in media supplemented with 5% FBS and
containing either 10 lM ATRA (closed squares) or ethanol control
(closed triangles) for the stated number of days before being counted.
N = 6. *P < 0.01. (B) For cells subjected to ﬂuorescent-activated
sorting, IEC6 cells were maintained in media containing 5% FBS and
10 lM ATRA (closed bars) or ethanol control (open bars) for the
stated periods of time. Each day, cells were harvested and analyzed by
FACS. Shown are the ratios of cells in the G1 and S phases of the cell
cycle. N = 5. *P < 0.001.
Fig. 2. A dose-response study of ATRA on KLF5 mRNA levels in IEC6 cell
cells treated with ATRA. Panel A is the result of a dose-response study in IE
and 50 lM. Panel C is a similar experiment except that the concentration of A
then GAPDH. Panels B and D represent densitometric quantiﬁcation of ba
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The mouse 1.5 kb KLF5 promoter linked to a luciferase reporter in
the pGL2-Basic vector was provided by Dr. A. Levine [25] and trans-
fected into IEC6 cells by lipofection along with a Renilla-luciferase re-
porter as a control. Transfected cells were treated with ethanol or 10
lM ATRA for 3 days before being harvested for reporter assays using
the Dual-Luciferase Reporter Assay protocol (Promega,Madison,WI).
2.4. Fluorescence-activated cell sorting analysis
Cell cycle analysis was performed using ﬂuorescence-activated cell
sorting (FACS) as previously described [26,27]. Cells were trypsinized,
washed with DPBS, and cooled to 20 C overnight in 70% ethanol.
Cells were then collected by centrifugation and stained with propidium
iodide (PI) solution (50 lg/ml PI, 50 lg/ml RNase A, 0.1% Triton X-
100, and 0.1 mM EDTA) for 25 min. Cells were analyzed using FAC-
SCalibur cytometer (Becton–Dickinson).
2.5. Western blot analysis
Cells were washed with DPBS and collected by centrifugation. The
cells were re-suspended in 1· lysis buﬀer (Cell Signaling, Beverly,
MA). The suspended cells were subjected to sonication and centrifuga-
tion. Western blot analysis was then performed using a rabbit poly-
clonal antibody against KLF5, hemagglutinin A (HA) (Santa Cruz
Biotech.) or b-actin (Oncogene Research).
2.6. Northern blot analysis
RNA was extracted using the Trizol protocol (Invitrogen, Carlsbad,
CA). Twenty micrograms of RNA was loaded onto a denaturing agar-
ose gel containing 10· MOPS buﬀer and 37% formaldehyde, and then
transferred to a nylon membrane (Hybond, Amersham, Piscataway,
NJ). Radioactive [a-32P] dATP was used to label cDNA probes for
KLF5 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
The membrane was hybridized in Quikhyb solution (Stratagene, La
Jolla, CA), washed under high-stringency conditions, and scanned
using a phosphorimager (Amersham).3. Results
We ﬁrst determined whether ATRA aﬀects growth and pro-
liferation of IEC6, a non-transformed rat intestinal epithelials. Northern blot analyses were conducted on RNA isolated from IEC6
C6 cells treated for 3 days with ATRA with a concentration between 0
TRA was between 0 and 1000 nM. Blots were probed with KLF5 and
nd intensities of KLF5 mRNA after normalizing to that of GAPDH.
Fig. 3. A time-course and promoter study of ATRA on KLF5 mRNA levels in IEC6 cells. Northern blot analyses were conducted on RNA isolated
from IEC6 cells treated with ethanol control (panel A) or 10 lM ATRA (panel B) on a daily basis up to 4 days after seeding. Panel C represents the
densitometric quantiﬁcation of band intensities of KLF5 mRNA after normalizing to that of GAPDH. In panel D, a 1.5 kb KLF5 promoter-
luciferase plasmid was transfected into IEC6 cells and treated with 10 lM ATRA (closed bar) or ethanol control (open bar) for 3 days before being
harvested for luciferase assays. Shown are the mean relative luciferase activities after normalizing for the internal Renilla luciferase control. N = 5.
*P < 0.01.
Fig. 4. Establishment of stably transfected IEC6 cells with KLF5.
IEC6 cells were transfected with pBK-CMV-KLF5-HA, selected with
G418 and pooled for the study. The resultant cells are designated
IEC6-KLF5. Shown are the results of Northern blot analysis (panel A)
and Western blot analysis (panel B) on the levels of KLF5 mRNA and
HA-tagged KLF5 protein from IEC6 and IEC6-KLF5. In panel C,
IEC6 or IEC6-KLF5 was seeded at a density of 105 cells/6-well dish
and propagated for 4 additional days. Cell numbers were determined
on a daily basis. N = 6. *P < 0.01.
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lM ATRA resulted in a signiﬁcant reduction in their rate of
proliferation between days 2 and 4 after seeding. This inhibi-
tory eﬀect was the consequence of cell cycle arrest at the
G1/S boundary as demonstrated by the signiﬁcant increase in
the G1/S ratios of cells treated with ATRA as compared to
control (Fig. 1B).
We next determined whether ATRA treatment aﬀects
expression of the gene encoding KLF5, previously shown to
be a pro-proliferative factor in IEC18 and NIH 3T3 cells
[11,22]. As shown in Fig. 2A and B, treatment of IEC6 cells
with ATRA from 5 to 50 lM for 3 days resulted in a dose-de-
pendent reduction in the levels of KLF5 mRNA. Treatment of
cells with lower doses of ATRA, between 1 and 1000 nM, re-
sulted in a less prominent and non-linear reduction in the levels
of KLF5 mRNA (Fig. 2C and D). For this reason, we used a
concentration of 10 lM throughout the present study.
We then performed a time-course study in IEC6 cells treated
with ATRA or ethanol control. In the presence of ethanol con-
trol, the levels of KLF5 mRNA increased over time (Fig. 3A).
In contrast, the levels of KLF5 mRNA in cells treated with 10
lM ATRA remained relatively unchanged for up to 4 days
(Fig. 3B). The relative abundance of KLF5 mRNA in treated
and control cells (Fig. 3C) paralleled that of their rates of pro-
liferation as illustrated in Fig. 1A. These results indicate that
ATRA inhibits expression of KLF5 in a dose-dependent and
time-dependent fashion, and that inhibition of KLF5 expres-
sion is correlated with a reduction in the rate of proliferation.
We then investigated the mechanism by which ATRA inhib-
its the expression of KLF5. We performed transfection studies
in IEC6 cells using a plasmid that contained 1.5 kb of the
KLF5 promoter linked to a luciferase reporter and treated
them with ATRA or ethanol control. Fig. 3D shows that treat-
ment of transfected IEC6 cells with 10 lM ATRA for 3 days
resulted in a statistically signiﬁcant reduction in the activityof the reporter construct when compared to ethanol control.
These ﬁndings suggest that the eﬀect of ATRA on KLF5
expression is mediated at the level of gene transcription.
Fig. 5. The eﬀect of ATRA on KLF5 expression, proliferation, and cell cycle proﬁle in untransfected and KLF5-transfected IEC6 cells. IEC6 and
IEC6-KLF5 cells were treated with 10 lM ATRA or ethanol control for 3 days before being harvested for Northern (panel A) or Western (panel B)
blot analyses. The antibody used in panel B is directed against KLF5. In panel C, IEC6-KLF5 cells were seeded at a density of 105 cells/6-well dish
and treated with 10 lM ATRA (closed squares) or ethanol (closed diamonds) for the stated number of days. N = 6. In panel D, IEC6-KLF5 cells
were treated as in panel C and analyzed by FACS on a daily basis. N = 5.
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eﬀect of ATRA on proliferation of IEC6 cells, we established
a stably transfected IEC6 cell line that constitutively expressedFig. 6. The eﬀect of ATRA on proliferation of human colon cancer cell line
(panel A), Caco2-BBE (panel B), HT29 (panel C), and RKO (panel D). For
maintained in the presence of 10 l M ATRA or ethanol control for up to 4 d
GAPDH in cells treated with ATRA (A) or ethanol control (E) for 3 days.KLF5 under the control of the cytomegalovirus (CMV) viral
promoter, which is not subject to regulation by ATRA. This
cell line, called IEC6-KLF5, contained a signiﬁcantly higher le-s. Four diﬀerent colon cancer cell lines were used in the study: DLD1
each cell line, cells were seeded at a density of 105 cells/6-well dish and
ays. N = 6. *P < 0.05. The insets show the mRNA levels of KLF5 and
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cells (Fig. 4A). In addition, when probed with an antibody
against HA, IEC6-KLF5 cells contained HA-tagged KLF5
protein, which was absent from untransfected cells (Fig. 4B).
As a consequence of stable and constitutive expression of
KLF5, IEC-KLF5 cells exhibited a higher rate of proliferation
when compared to the untransfected IEC6 cells (Fig. 4C).
Importantly, treatment of IEC6-KLF5 with 10 lM ATRA
failed to reduce the levels of KLF5 mRNA and protein as
shown in Fig. 5A and B, respectively. In comparison, the levels
of KLF5 mRNA and protein were reduced in untransfected
IEC6 cells that were treated with ATRA (Fig. 5A and B).
Moreover, constitutive expression of KLF5 in IEC6 cells re-
sulted in resistance to ATRA as demonstrated by the lack of
eﬀect of ATRA on the rate of proliferation and cell cycle pro-
ﬁle, illustrated in Fig. 5C and D, respectively. These results
suggest that the inhibitory eﬀect of ATRA on IEC6 cells is pri-
marily mediated by the ability of ATRA to inhibit endogenous
KLF5 expression.
To determine whether ATRA may have an eﬀect on prolif-
eration of human colon cancer cell lines, we cultured several
established colon cancer cell lines in the presence or absence
of 10 lM ATRA. The growth rates of three cell lines,
DLD1, Caco2-BBE and HT29, were sensitive to ATRA treat-
ment (Fig. 6A, B and C, respectively). However, the rate of
proliferation of RKO cells was indiﬀerent to ATRA (Fig.
6D). A diﬀerence between the ﬁrst three cell lines and RKO
cells is that the basal level of KLF5 mRNA is signiﬁcantly
lower in RKO cells as compared to the ﬁrst three cell lines
(Fig. 6, insets). Importantly, the ability of ATRA to reduce cell
proliferation is correlated with a reduction in the levels of
KLF5 mRNA in DLD1, Caco2-BBE and HT29 cells (Fig. 6,
insets). In RKO cells, the level of KLF5 mRNA was un-
changed with ATRA treatment (Fig. 6D, inset). These results
further suggest that KLF5 mediates the inhibitory eﬀect of
ATRA on IEC proliferation.4. Discussion
Retinoids are known to play a vital role in various physio-
logical processes such as embryogenesis, growth, diﬀerentia-
tion and reproduction [28]. Studies also showed that retinoic
acid can inhibit proliferation of many tumor cells grown in vi-
tro [29]. These ﬁndings led to the successful clinical application
of retinoids in the treatment or prevention of various human
cancers, such as APL [18]. In the case of APL, ATRA is able
to induce complete remission in almost all patients by inducing
in vivo diﬀerentiation of blast cells in APL [18].
Numerous studies have demonstrated that the cellular eﬀects
of retinoids are mediated by nuclear receptors, including
RARs and RXRs [12]. For example, the inhibitory eﬀect of
ATRA on proliferation of the human colon cancer cells,
HT29, is mediated through RARa [19]. Also, induction of
RAR in the retinoid-resistant colon cancer cells, LoVo, re-
stored retinoid sensitivity [30]. Despite these ﬁndings, the
mechanisms by which ATRA inhibits tumor cell proliferation
remain poorly established.
In the current study, we characterized the anti-proliferative
eﬀect of ATRA on a non-transformed rat IEC line, IEC6.
Our results showed that ATRA inhibits cell proliferation inIEC6 (Fig. 1A). This inhibitory eﬀect is primarily due to an ar-
rest in the G1to S transition of the cell cycle (Fig. 1B). A sim-
ilar eﬀect of ATRA on the cell cycle has previously been
demonstrated in myeloid cells [31] and ovarian carcinoma cells
[32]. In myeloid cells, ATRA-induced cell cycle arrest is accom-
panied by downregulation of c-Myc and cyclin E [33], the lat-
ter an essential component for G1 to S transition. ATRA has
also been shown to reduce expression of protein kinase C a
(PKCa) and activity of the mitogen-activated protein kinase
(MAPK) pathway [34].
The Kru¨ppel transcription factor, KLF5, has been shown to
positively regulate cell proliferation in NIH 3T3 ﬁbroblasts
and IEC [11,22]. Results of our present study indicate that
ATRA inhibits expression of KLF5 in IEC6 cells (Figs. 2
and 3) by inhibiting the promoter activity of KLF5 (Fig.
3D). The reduction in KLF5 mRNA levels due to ATRA treat-
ment is correlated with a reduction in the rate of proliferation
(Figs. 1 and 3C). The dosage of ATRA that we chose was rel-
atively high at 10 lM, based on the result of the dose-response
experiment in Fig. 2. Several other studies have used lower
dosages [35,36]. However, numerous studies have also used
higher concentrations of ATRA similar to ours in order to
accomplish the inhibitory eﬀects of ATRA in various cell lines
[37–40]. Therefore, the diﬀerent sensitivity of diﬀerent cell lines
to ATRA is probably a cell type-speciﬁc event.
IEC6 cells stably transfected with a viral promoter-driven
KLF5-expression vector contained a higher level of KLF5
mRNA and protein and a higher rate of proliferation as com-
pared to untransfected IEC6 cells (Fig. 4). When treated with
ATRA, the levels of KLF5 mRNA and protein were not de-
creased in IEC6-KLF5 cells as opposed to untransfected
IEC6 cells (Fig. 5A and B). This is primarily due to the consti-
tutive expression of KLF5 from a viral promoter that is not af-
fected by ATRA. This constitutive expression resulted in the
IEC-KLF5 cells to resist the inhibitory eﬀect of ATRA as dem-
onstrated in Fig. 5C and D. These results suggest that KLF5 is
a mediator for the inhibitory eﬀect of ATRA on proliferation
of IEC6 cells, although we could not rule out KLF5-independ-
ent mechanisms. It is of interest to note that KLF5 expression
is stimulated by the phorbol ester, PMA, a potent activator of
PKCa [11,41]. Moreover, studies indicate that KLF5 expres-
sion is stimulated by MAPK activation [41,42]. The fact that
ATRA inhibits both PKCa and MAPK [34] may be a mecha-
nism by which it inhibits KLF5 expression. It should be noted
that cyclin D1 has been shown to be a target of regulation by
KLF5 [42]. The eﬀect of ATRA on G1 progression can there-
fore be a consequence of its ability to inhibit cyclin D1 expres-
sion through KLF5.
ATRA has previously been shown to inhibit proliferation
of some, but not all, colon cancer cells [19–21,30]. Our study
demonstrated that 3 colon cancer cell lines, including DLD1,
Caco2-BBE and HT29, are sensitive to the inhibitory eﬀect
of ATRA but RKO cells are resistant (Fig. 6). Previous stud-
ies suggest that the presence or absence of RARs in cells ap-
pears to play a role in determining whether cells are sensitive
or resistant to ATRA treatment [21,30]. However, all of the
cells that we examined contain RARa (data not shown). In-
stead, the ability of ATRA to inhibit cell proliferation is di-
rectly correlated with a reduction in KLF5 mRNA levels in
the 3 sensitive cell lines (Fig. 6A, B and C). The lone cell
line, RKO, that is resistant to ATRA action, contains little
KLF5 mRNA at baseline, which is not changed with ATRA
104 S. Chanchevalap et al. / FEBS Letters 578 (2004) 99–105treatment (Fig. 6D). These results further support the role of
KLF5 in mediating the inhibitory eﬀect of ATRA on cell
proliferation. Furthermore, whether a tumor cell is sensitive
to ATRA may in part be determined by the degree of
KLF5 expression.
The relationship between KLF5 and retinoids in regulating
cell proliferation has also been demonstrated in vivo [23]. This
was shown by the ability of RAR ligands to modulate KLF5
transcriptional activity. Moreover, RAR and KLF5 physically
interact. A consequence of this relationship is the ability of a
RAR agonist, Am80, to inhibit vascular remodeling in vivo,
a process that is dependent on KLF5 [23]. Whether RAR
and KLF5 physically interact in IEC is unclear at this time.
In conclusion, our study demonstrated an important role for
KLF5 in mediating the inhibitory eﬀect of ATRA on prolifer-
ation of IEC. We also showed that diﬀerential sensitivity of
colon cancer cells to ATRA may be due to diﬀerential levels
of KLF5 expression. Additional correlation between KLF5
expression and ATRA sensitivity in other cell lines may further
substantiate the role of KLF5 in modulating IEC proliferation.
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